Advertisement

Topics

Extended treatment with Brilinta reduces risk of cardiovascular death by 29% in patients with history of heart attack

07:39 EDT 24 Aug 2017 | World Pharma News

AstraZenecaAstraZeneca today announced results from a new sub-analysis of data from the Phase III PEGASUS-TIMI 54 trial demonstrating a 29% risk reduction in CV death (p=0.0041) from treatment with Brilinta (ticagrelor) 60mg twice daily, versus placebo, in patients taking low-dose aspirin but still at high risk of an atherothrombotic event, a major cause of acute coronary syndrome and CV death.

Original Article: Extended treatment with Brilinta reduces risk of cardiovascular death by 29% in patients with history of heart attack

NEXT ARTICLE

More From BioPortfolio on "Extended treatment with Brilinta reduces risk of cardiovascular death by 29% in patients with history of heart attack"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...